Market Cap

Inhibikase Therapeutics, Inc. Market Capitalization:

$8.3 Million

USD as of Jan. 1, 2024

business Inhibikase Therapeutics, Inc. Company Profile

Inhibikase Therapeutics, Inc. Main Stock Listing

NASDAQ: IKT

Market Capitalization History of Inhibikase Therapeutics, Inc.

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Top Competitors by Market Capitalization

Industry: Biotechnology
Company Market Cap (USD)
Novo Nordisk $622.07 B
Vertex Pharmaceuticals Incorporated $121.36 B
Regeneron Pharmaceuticals, Inc. $115.11 B
CSL Limited $95.75 B
Marinomed Biotech AG $75.67 B
Sector: Healthcare
Company Market Cap (USD)
Lilly $808.65 B
Novo Nordisk $622.07 B
UnitedHealth Group $450.89 B
Johnson & Johnson $350.63 B
Merck $318.75 B

Yearly evolution of Inhibikase Therapeutics, Inc. market cap

Date Market Cap YoY Change
Jan. 1, 2024 $8.3 M -50.51%
Jan. 1, 2023 $16.7 M -51.43%
Jan. 1, 2022 $34.4 M -78.98%
Jan. 1, 2021 $163.7 M

Market capitalization is calculated from the opening stock price at the beginning of each year.

Top 1-year algo backtest: +265.99%

$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.

Use AI to boost your investing & swing trading, now!

Try Disfold DeepFinance FREE

Inhibikase Therapeutics, Inc. Categories

United States languages Healthcare languages Biotechnology
United States Healthcare United States Biotechnology

Stocks & Indices

Inhibikase Therapeutics, Inc. has the following listings and related stock indices.


Stock: NASDAQ: IKT

What is a company's market capitalization?

The market capitalization of a company, more simply referred to as "market cap", is the total market value of a publicly traded company's outstanding shares. It is often considered as a key indicator of what a company is worth.